

Haematologica  
HAEMATOL/2017/178384  
Version 4

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma

Ziduo Li, Xinsheng Ju, Kenneth Lee, Candice Clarke, Jennifer L. Hsu, Edward Abadir, Christian E. Bryant, Suzanne Pears, Neroli Sunderland, Scott Heffernan, Annemarie Hennessy, Tsun-Ho Lo, Geoffrey A. Pietersz, Fiona Kupresanin, Phillip D. Fromm, Pablo A. Silveira, Con Tsonis, Wendy A. Cooper, Ilona Cunningham, Christina Brown, Georgina J. Clark, and Derek N.J. Hart

Collaborative Groups: Australia National Health and Medical Research Council Development Grant), Cancer Institute NSW Translation Program Grant)

Disclosures: D.N.J.H. and G.C. are both Directors and C.T. the CEO, of DendroCyte BioTech Pty Limited, which holds patents for humanized anti-CD83 mAb, 3C12C. The remaining authors declare no conflict of interest.

Contributions: Z.L., X.J., K.L., C.C., J.L.H., C.E.B., S.P., N.S., S.H., A.H., T.L., G.P., F.K., W.A.P., P.D.F., P.A. S., I.C., C.B. performed experiments and/or provided the patient and nonhuman primate samples; Z.L., X.J., E.A., G.J.C., and D.N.J.H. analyzed results and made the figures; X.J., C.T. and D.N.J.H. designed the experiments; X.J. and D.N.J.H. wrote the paper.